Logo image
The Surveillance After Extremity Tumor Surgery (SAFETY) trial: protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial
Journal article   Open access   Peer reviewed

The Surveillance After Extremity Tumor Surgery (SAFETY) trial: protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial

Michelle Ghert, Mohit Bhandari, Anthony Bozzo, P. D. Sander Dijkstra, Anthony Griffin, Robert Grimer, James Hayden, Arlene Manherz, Karim Masrouha, Paula McKay, …
BMJ open, Vol.9(9), pp.e029054-e029054
09/01/2019
DOI: 10.1136/bmjopen-2019-029054
PMCID: PMC6756324
PMID: 31537562
url
https://doi.org/10.1136/bmjopen-2019-029054View
Published (Version of record) Open Access

Abstract

Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2x2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms(1): chest radiograph (CXR) every 3 months for 2 years(2); CXR every 6 months for 2 years(3); chest CT every 3 months for 2 years or(4) chest CT every 6 months for 2years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study.
General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology

Details

Logo image